drugset / Trial / NCT00219882
Safety Study of Orally Administered Curcuminoids in Adult Subjects With Cystic Fibrosis
Phase 1
Completed
11 enrolled
Ramsey, Bonnie, MD
CF Therapeutics Development Network Coordinating Center · collabCystic Fibrosis Foundation · collabSeer Pharmaceuticals · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety of advancing doses of curcuminoids administered orally for fourteen consecutive days in adult subjects with cystic fibrosis (CF) who are homozygous for ΔF508 CFTR.
Timeline
- Start
- 2005-04
- Primary completion
- —
- Completion
- 2006-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Curcumin | Small molecule | 3 g | Oral |